Skip to main content

    Abhineet Shrivastava
    1, Soumyanath Mishra2
    1 Manager, Overseas business development department Coating and Engineering material division, Mitsui Chemicals Inc
    2 Head, Packaging development, Mankind Pharmaceutical Ltd.

    Environment pollution : Case of China and what India can learn from it

    As global economy is growing, the problem of environment pollution is also increasing rapidly and now it cannot be overlooked anymore. Indeed it is imperative for countries globally to restore their ecological environment. In 2016 the World health Organization (WHO) released a report on atmospheric pollution. In this report it is said that 92% of the world’s population are exposed to atmospheric pollution of hazardous level. Data from International Energy Agency (IEA) also shows that in 2016 , 6.5 million died as a result of atmospheric pollution. One of the cause for atmospheric pollution is the use of organic solvents during industrial production. Therefore, a matter that urgently needs to be addressed is the reduction of use of organic solvent in order to reduce VOC emission.


    As per analysis of United States Government Accountability Office (GAO), preliminary analysis of Food and Drug Administration (FDA) data shows that from fiscal year 2012 through 2016, the number of foreign drug manufacturing establishment inspections increased. From fiscal year 2016 through 2018, both foreign and domestic inspections decreased by about 10 percent and 13 percent, respectively.

  • Highest Pharmaceutical mergers and acquisitions of 2019

    Mergers and acquisitions (M&As) are perpetual part of big pharmaceutical industries and we have witnessed many such mergers and acquisitions. The financial crisis and resulting uncertainty in the global economies has made it difficult for companies to predict future performance of their own or their target’s or to forecast synergies and other transaction benefits with the same level of confidence seen in the past. As a result, acquirors and targets have developed transaction structures that are aimed at bridging gaps in their respective assessments of valuation and risk.

    This article is focusing on top Pharmaceutical M&As of the year 2019.

  • Metabolic Syndrome : A Review

    Navneet Kaur1, Narinder Singh2, Daisy Sharma2.
    1Department of Biotechnology, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar-144001, Punjab.
    2Department of Pharmaceutics, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar-144001, Punjab

    Metabolic syndrome is defined by a group of interconnected physiological and a few biochemical or clinical disorder which directly affect the high risk rate of diseases such as cardiovascular disease (hypertension) also causing type 2 diabetes mellitus and mortality. The metabolic syndrome is higher prevalence in Western counterparts other than the urban population of some emerging countries. In the review Definition of syndrome, pathophysiology, and some criteria would be proposed for the clinical diagnosis and underlying management approaches for metabolic syndrome.

  • Can India ever demolish misuse of antibiotics?

    Antibiotic resistance (AMR) is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Antimicrobial Resistance is an increasingly serious threat to public health. The spread of multi-drug resistant bacteria and the lack of new antibiotics to treat infections caused by these organisms pose a rapidly increasing threat to human health which urgently needs to be tackled.


    Orphan drugs are medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases or disorders that are rare. In USA, the Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare diseases. India does not have laws on orphan drugs though CDSCO defined orphan drugs as those intended to treat a condition which affects fewer than 200,000 people.

  • Decreasing Therapy Cost, For people by People: Collobrative approach

    Development of new biopharmaceutical for different patient's need is now in some limited hand due to high R&D (Research and Development) cost and making therapy are not affordable for large segment of people in developing country.

  • How to register as pharmacist in USA from any foreign countries including India?

    United States half pharmacies are located within drug stores, grocery stores, hospitals, department stores, medical clinics, surgery clinics, universities, nursing homes, prisons, and other facilities. The remaining pharmacies are considered to be independent or privately owned. In USA, average salary of pharmacists is 99000-140000 USD per annum. It can be varied depending on many factors.

  • Operant Pharmacy Federation – Powered by Researchers for Emerging Innovation

    Very soon we are going to see a huge gap for “right talent” in Indian pharma industry. In my view following could be the reasons and steps to be taken by industry:

    1. Gender:
    a. At +2 level, boys are for engineering, girls are for medicine, and those who fail to get medical seats opt for pharmacy. Hence there is an increase in trend of girls graduating out of pharmacy colleges.
    b.  Most of Indians prefer their girl child to get married immediately after graduation or sometimes even when they are in their final years of course. (The latest demographic indicators provided by the health and family welfare ministry reveal that the national average age of marriage for girls was 20.6 years in 2008, up from 18.3 years in 2001.
    c. After marriage probability of girl continuing higher studies or getting into job is reduced.
    d. Most of recruiters have bias in considering girls as they are uncertain on when these girls leave the job for the reasons of marriage, re-location due to husband’s place of job or maternity.

Subscribe to Articles

Search this website